Oral gallium maltolate for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests an oral drug called gallium maltolate for people whose glioblastoma (a type of brain cancer) has returned after standard treatment. The drug is given by mouth and may help slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of glioblastoma (a type of brain cancer) that has come back after standard treatment.
- You must have completed standard treatment (radiation and temozolomide) at least 4 weeks before starting the study drug.
- You must be stable enough to undergo a surgical biopsy or resection of the tumor.
- You must be able to swallow and keep down oral medication.
- You must not have other active cancers (except certain skin cancers) or severe heart/lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial gives access to gallium maltolate, an oral investigational drug, for people whose glioblastoma has returned and who have no other good options. The goal is to see if it can help control the tumor.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This study tests a light-activated therapy (radiodynamic therapy) using a special medicine to help treat a brain tumor that has come back after prior treatment. It may be offered after doctors decide you need further radiation for your recurrence.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests an oral liquid medicine called gallium maltolate in children with high-grade gliomas or atypical teratoid rhabdoid tumors that have come back or not responded to standard treatment. The goal is to see if it can help shrink or control the tumor.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.